대웅제약

"What science lies behind an injection that works for a long time with just a single dose?"💉 Long-acting injectable formulations(depot injections) operate on a principle where polymer materials encapsulate the drug and release it gradually over time. The challenge is that even minute differences in the polymer can completely alter the drug release profile, making it far from straightforward to scientifically demonstrate equivalence to the originator product. Ms. 박초롱, a researcher from the Platform Analysis Team in the CMC division at 대웅제약, designed an evaluation roadmap from the ground up in a landscape where global regulatory frameworks exist but detailed guidelines are lacking. Through multi-angle analyses, including NMR and GPC-3D, she established structural equivalence of the polymer. By strategically combining internal capabilities with collaborations with external specialized institutions, she successfully built a proprietary analytical system. Discover 박초롱’s story in the video now. 👉https://lnkd.in/g_sCD6_E

We are delighted to introduce high-precision liver organoid production and drug evaluation technologies through our collaboration with Dr. Myung-Jin Son's team, who is leading the OECD Test Guideline Project (DRP) and ISO international standards. Moving forward, we are fully committed to advancing this liver organoid technology and delivering tangible, impactful breakthroughs in drug discovery.

#News 📣 대웅제약(Shawn (Seongsoo) Park) has signed a technology in-licensing agreement with Korea Research Institute of Bioscience and Biotechnology (KRIBB) for the generation of liver organoids and drug evaluation technology.🤝 The acquired technology is recognized as a highly mature platform backed by robust empirical data among domestic and international liver organoid technologies. KRIBB’s 3D liver organoids precisely mimic human liver tissue and intrahepatic bile ducts, dramatically enhancing the accuracy of preclinical liver toxicity assessments, which have historically been challenging to predict using animal models. Through this agreement, Daewoong Pharmaceutical aims to elevate its nonclinical evaluation system beyond international benchmarks and significantly reinforce its global competitiveness in new drug development.💫 🔗 Read the full article here https://lnkd.in/gW4cKKse #대웅제약 이 #한국생명공학연구원 과 ‘간(Liver) 오가노이드 제작 및 약물평가 기술’ 도입을 위한 기술이전 계약을 체결했습니다. 이번에 확보한 기술은 국내외 간 오가노이드 기술 중 높은 수준의 완성도와 실증 데이터를 갖춘 플랫폼으로 평가받고 있습니다. 생명연의 3차원 간 오가노이드는 인간의 간 조직과 담즙산 배출 구조인 ‘간내 담관’까지 정밀하게 모사해, 동물실험으로도 확인하기 어려웠던 임상 전 단계의 간 독성 평가 정확도를 획기적으로 높였습니다. 대웅제약은 이번 기술 도입을 통해 비임상 평가 체계를 국제 표준 수준 이상으로 고도화하고, 글로벌 신약 개발 경쟁력을 대폭 강화할 예정입니다.

#Breakingnews 📣 대웅제약’s in-house developed botulinum toxin has surpassed KRW 1 trillion in cumulative sales (as of June 30, 2026). This global achievement has also contributed to the overall expansion of the nation’s biopharmaceutical exports. According to a recent announcement by MFDS(Ministry of Food and Drug Safety) , biopharmaceutical exports reached USD 4.5 billion in the first half of 2026, marking an all-time high and setting consecutive records in both the first and second quarters. 대웅제약’s botulinum toxin has gained strong traction in the global market, supported by approvals from major regulatory authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada. JUNSOO YUN, Head of the Nabota Business Division at 대웅제약, stated, “Achieving KRW 1 trillion in cumulative sales within just over a decade is a meaningful milestone that reflects both the product’s quality competitiveness and our global market strategy. Moving forward, we will continue to expand our global presence and build a next-generation aesthetic portfolio, aiming to grow our botulinum toxin into a global blockbuster brand with annual sales of KRW 500 billion by 2030”. 🔗 Read the full article here https://lnkd.in/gjPGBvai 대웅제약의 자체 개발 보툴리눔 톡신의 누적 매출이 1조원을 돌파했습니다. (2026년 6월 30일 기준) 이 같은 글로벌 성과는 국가 전체 바이오의약품 수출 확대에도 힘을 보탰습니다. 최근 식품의약품안전처 발표에 따르면 2026년 상반기 바이오의약품 수출액은 45억 달러로 역대 최대 실적을 기록했으며, 1분기와 2분기 연속으로 최대치를 경신했습니다. 대웅제약의 보툴리눔 톡신은 미국 식품의약국(FDA), 유럽의약품청(EMA), 캐나다 보건부(Health Canada) 등 주요 규제기관의 허가를 바탕으로 글로벌 시장에서 두각을 드러내고 있습니다. 윤준수 대웅제약 나보타사업본부장은 "10여 년 만에 달성한 누적 매출 1조원은 보툴리눔 톡신의 품질 경쟁력과 글로벌 시장 전략이 만들어낸 성공적인 성과"라며, "앞으로도 글로벌 시장 확대와 차세대 에스테틱 포트폴리오 구축을 통해 보툴리눔 톡신을 2030년 연매출 5,000억원 규모의 글로벌 블록버스터 브랜드로 성장시켜 나가겠다"고 말했습니다. #Daewoong #Pharmaceutical #botulinumtoxin #global #market #blockbuster #대웅제약 #식품의약품안전처 #보툴리눔톡신

#News 📣 대웅제약 has entered into a distribution agreement with Waycen Inc.(Kyungnam(James) Kim), a medical AI company, for the AI-powered endoscopic image analysis software 'WAYMED ENDO', marking an expansion of its digital healthcare business. “WAYMED ENDO” is Korea’s first AI-based real-time endoscopic image analysis software for the stomach and colon. It supports the detection of lesions that are easily missed by the naked eye during examinations, such as those hidden behind mucosal folds, located at the edges, or as small as 2–3 mm. The AI also automatically measures key endoscopy quality indicators, including examination time and withdrawal time, thereby contributing to improved quality management and workflow efficiency for medical professionals. Through this partnership, 대웅제약 plans to enhance its existing portfolio of gastrointestinal treatments—including therapies for gastroesophageal reflux disease (GERD) and bowel cleansing agents—by integrating AI-assisted diagnostic software. This will enable the company to offer a comprehensive 'total solution for gastrointestinal diseases', covering the entire continuum from examination and diagnosis to treatment. 🔗 Read the full article here https://lnkd.in/g73VPUgQ 대웅제약이 의료 AI 전문기업 웨이센과 AI 내시경 영상 분석 소프트웨어 ‘웨이메드 엔도’ 판매 위탁 계약을 체결하고, 디지털 헬스케어 사업 확대에 나섭니다. ‘웨이메드 엔도’는 국내 최초 AI 기반 위·대장 내시경 실시간 영상 분석 의료 소프트웨어로, 내시경 주름 뒤나 가장자리, 2~3mm 크기의 작은 병변 등 육안으로 놓치기 쉬운 병변을 검사 중 확인할 수 있도록 지원합니다. AI가 검사 시간과 회수 시간 등 주요 내시경 품질 지표를 자동으로 측정해 의료진의 검사 품질 관리와 업무 효율 향상에 기여합니다. 이번 협력으로 대웅제약은 위식도역류질환 치료제와 대장 정결제 등 기존 소화기 질환 제품군에 AI 진단 보조 소프트웨어를 더해 검사부터 진단, 치료까지 아우르는 '소화기 질환 토털 솔루션'을 제공할 계획입니다. #Daewoong #Pharmaceutical #WAYMEDENDO #Waycen #대웅제약 #웨이센 #웨이메드엔도

#News 📣 Recent findings suggest that the novel antidiabetic agent #enavogliflozin may improve fatty liver in patients with type 2 diabetes. This study indicates that the therapy could extend beyond glycemic control to address fatty liver disease, a common comorbidity associated with diabetes.💊 The study results were published in the SCI-indexed international journal Diabetes, Obesity and Metabolism (#DOM).📝 Given that metabolic dysfunction-associated fatty liver disease (#MAFLD) has a high comorbidity rate of over 65% among patients with type 2 diabetes, these findings may provide supporting evidence for the expanded therapeutic value of enavogliflozin in real-world clinical practice.💫 🔗 Read the full article here https://lnkd.in/gcyz3N3P 당뇨병 신약 이나보글리플로진의 2형당뇨병 환자 대상 지방간 개선 가능성을 확인했습니다. 이번 연구는 동 치료제가 혈당 조절을 넘어 당뇨병 동반 질환인 지방간까지 관리하는 치료제로 확장될 수 있음을 의미합니다. 관련 연구 결과는 SCI급 국제 저명 학술지 'Diabetes, Obesity and Metabolism, DOM'에 게재됐습니다. 대사이상지방간질환은 2형당뇨병 환자에게 약 65% 이상의 높은 동반율을 보이는 만큼, 이번 연구는 실제 진료 환경에서 동 치료제의 치료적 가치 확장 가능성을 뒷받침하는 근거가 될 것으로 기대됩니다. 

A major leap forward in our global commercialization strategy. We are thrilled to partner with Acino Pharma AG to bring enavogliflozin to 8 major Middle Eastern and African nations, including Saudi Arabia and the UAE. This USD 94 million agreement stands as our largest licensing deal for enavogliflozin to date. We look forward to a successful launch by 2027, providing an advanced and effective therapeutic option for patients with impaired renal function.

#News 📢 Post-marketing surveillance (PMS) interim analysis results evaluating the effectiveness and safety of #fexuprazan hydrochloride, a treatment for gastroesophageal reflux disease (GERD), in real-world clinical practice have been published in the SCIE-indexed international journal Gut and Liver in the field of gastroenterology. 📄💊 The study demonstrated that symptom improvement was observed in the majority of patients following treatment with fexuprazan. In terms of safety, no serious adverse drug reactions were reported, and the overall incidence of adverse drug reactions was low. Notably, consistent therapeutic effects were observed across diverse patient groups, including elderly patients aged 65 years and older, patients with comorbidities such as hypertension and diabetes, and those receiving multiple concomitant medications. These findings support its use as a viable treatment option for a broad range of patients in real-world clinical settings. Moving forward, we will continue to build robust clinical evidence for fexuprazan through further research and strengthen its overall competitiveness.💡 🔗 Read the full article here https://lnkd.in/gvqwAS4c 위식도역류질환 치료제 펙수프라잔염산염이 실제 진료 환경에서의 효과와 안전성을 평가한 시판 후 조사(PMS) 중간 분석 결과가 소화기학 분야 SCIE급 국제 학술지인 ‘Gut and Liver’에 게재됐습니다. 연구 결과, 펙수프라잔 투여 후 전체 환자의 대부분에서 증상 개선이 확인됐습니다. 안전성 측면에서도 중대한 이상약물반응은 보고되지 않았으며, 전체 이상약물반응 발생률도 낮은 수준을 보였습니다. 특히 65세 이상 고령 환자와 고혈압·당뇨 등 동반질환 환자, 여러 약물을 함께 복용 중인 환자군에서도 일관된 치료 효과가 나타나, 실제 진료 환경에서 폭넓은 환자군에 사용할 수 있는 치료 옵션임을 확인했습니다. 앞으로도 다양한 연구를 바탕으로 펙수프라잔의 의학적 근거를 마련하고 경쟁력을 강화해 나가겠습니다. #Daewoong #GERD #gastroenterology #GutandLiver #PMS #대웅제약 #펙수프라잔 #위식도역류질환

#News 📢 대웅제약 entered into an out-licensing agreement with Acino Pharma AG (Arcera Life Sciences) for enavogliflozin, covering eight key countries across the Middle East and Africa, including Saudi Arabia and the United Arab Emirates.✍🏻 The total deal value amounts to approximately KRW 145.2 billion(USD 93,983,086), including milestone payments. This represents the largest licensing agreement for enavogliflozin since its global commercialization and marks the first case of a domestically developed SGLT-2 inhibitor for diabetes entering the Middle East and African markets. As a next-generation SGLT-2 inhibitor, enavogliflozin delivers exceptional blood glucose-lowering efficacy at a lower dosage and offers proven therapeutic benefits even for patients with impaired renal function.💊 Following this agreement, 대웅제약 aims to obtain marketing approval in Saudi Arabia within this year and plans to launch the product across the eight Middle Eastern and African countries starting in the first half of 2027.🌍 🔗 Read more https://lnkd.in/gEYRdddP 대웅제약이 사우디아라비아, 아랍에미리트 등 중동·아프리카 주요 8개국을 대상으로 한 이나보글리플로진 라이선스 아웃 계약을 아시노(Acino Pharma AG)와 체결했습니다. 총 계약 규모는 마일스톤을 포함해 한화 약 1,452억 원으로, 이나보글리플로진의 글로벌 사업화 이후 체결된 계약 가운데 최대 규모이자, SGLT-2 억제제 계열 국산 당뇨병 신약이 중동·아프리카 시장에 진출하는 최초 사례입니다. 이나보글리플로진은 기존 SGLT-2 억제제 대비 저용량으로도 우수한 혈당 강하 효과를 나타내며, 특히 신기능 저하 환자군에서도 뛰어난 효능과 안전성을 입증한 당뇨병 신약입니다. 이번 계약을 기점으로 사우디아라비아에서 올해 품목 허가를 획득하고, 2027년 상반기부터 중동·아프리카 8개국 출시를 목표로 하고 있습니다. #Daewoong #enavogliflozin #AcinoPharmaAG #licensingout #agreement

Most long-acting depot formulations still struggle with one critical challenge: the initial burst — a sudden spike in drug concentration right after injection that can trigger nausea, vomiting, and early treatment discontinuation.💉 In Episode 3 of the "Maximizing Therapeutic Potential with CURE®" series, we explore how CURE® controls the initial burst at the structural level. EP.1🔗 https://lnkd.in/gJSRrbdm EP.2🔗 https://lnkd.in/gEDjzJyk Learn more👉https://lnkd.in/exTA5BHB #Daewoong #GLP1 #CURE #platform #obesity #diseases #longactinginjectables #InitialBurst